Skip to main content
SpringerLink
Log in
Book cover

Renal Denervation pp 107–116Cite as

Perivascular Renal Denervation (PVRDTM): Chemical Renal Denervation with Micro-Doses of Ethanol Using the PeregrineTM Renal Denervation Device

  • Chapter
  • First Online:

  • 872 Accesses

Abstract

In the 1930s–1950s surgical renal sympathectomy was used to treat severe hypertension [1–3]. Despite a successful lowering of blood pressure (BP) observed with surgical denervation, this technique was abandoned due to a relatively high morbidity and mortality, and as a result of the development of more effective oral antihypertensive medications

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Harris SH. Renal sympathectomy: its scope and limitations. R Soc Med. 1935;28:1497–510.

    CAS  Google Scholar 

  2. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152:1501–4.

    Article  CAS  PubMed  Google Scholar 

  3. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54(6):1195–201.

    Article  CAS  PubMed  Google Scholar 

  4. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.

    Article  PubMed  Google Scholar 

  5. Investigators, SH-1. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.

    Article  Google Scholar 

  6. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903–9.

    Article  PubMed  Google Scholar 

  7. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126:2976–82.

    Article  CAS  PubMed  Google Scholar 

  8. Kandzari DE, Bhatt DL, Sobotka PA, O’Neill WW, Esler M, Flack JM, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clin Cardiol. 2012;35:528–35.

    Article  PubMed  Google Scholar 

  9. Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419–24.

    Article  CAS  PubMed  Google Scholar 

  10. Krum H, Schlaich M, Sobotka P, Scheffers I, Kroon AA, de Leeuw PW. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation. 2011;123:209–15.

    Article  PubMed  Google Scholar 

  11. Lambert GW, Hering D, Esler MD, Marusic P, Lambert EA, Tanamas SK. Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension. 2012;60:1479–84.

    Article  CAS  PubMed  Google Scholar 

  12. Ormiston JA, Watson T, van Pelt N, Stewart R, Haworth P, Stewart JT. First-in-human use of the OneShot™ renal denervation system from Covidien. EuroInterv. 2013;8:1090–4.

    Article  Google Scholar 

  13. Schlaich MP, Hering D, Sobotka PA, Krum H, Esler MD. Renal denervation in human hypertension: mechanisms, current findings, and future prospects. Curr Hypertens Rep. 2012;14:247–53.

    Article  PubMed  Google Scholar 

  14. Schlaich MP, Krum H, Sobotka PA, Esler MD. Renal denervation and hypertension. Am J Hypertens. 2011;24:635–42.

    Article  PubMed  Google Scholar 

  15. Cook S, Goy J, Togni M. Optical coherence tomography findings in renal denervation. Eur Heart J. 2012;10:1093.

    Google Scholar 

  16. Kaltenbach B, Id D, Franke JC, Sievert H, Hennersdorf M, Maier J, Bertog S. Renal artery stenosis after renal sympathetic denervation. J Am Coll Cardiol. 2012;60(25):2694–5.

    Article  PubMed  Google Scholar 

  17. Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet. 2012;380:778.

    Article  PubMed  Google Scholar 

  18. Virmani R. Perirenal nerve distribution, density and quantification: implications for the evaluation of device safety and efficacy. Presentation at TCT Conference, 2012, TCT 2012. p. 1–32 http://www.tctmd.com/show.aspx?id=114463.

  19. Fischell TA, Vega F, Raju N, Johnson ET, Kent DJ, Ragland RR, Almany ST, Fischell DR, Ghazzorossian VE. Ethanol-mediated perivascular renal denervation: preclincal validation of safety and efficacy in a porcine model. EuroInterv. 2013;9:140–7.

    Article  Google Scholar 

  20. Sobotka PA, Krum H, Bohm M, Francis DP, Schlaich MP. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep. 2012;14:285–92.

    Article  PubMed  Google Scholar 

  21. Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger H-R, Wirth K, et al. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension. 2012;60:172–8.

    Article  CAS  PubMed  Google Scholar 

  22. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559–65.

    Article  CAS  PubMed  Google Scholar 

  23. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901–9.

    Article  PubMed  Google Scholar 

  24. Schlaich MP, Hering D, Sobotka P, Krum H, Lambert GW, Lambert E. Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension. Front Physiol. 2012;3:10.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940–6.

    Article  CAS  PubMed  Google Scholar 

  26. Schlaich MP, Bart B, Hering D, Walton A, Marusic P, Mahfoud F. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol. 2013;168(3):2214–20.

    Article  PubMed  Google Scholar 

  27. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Linz D, Mahfoud F, Schotten U, Ukena C, Hohl M, Neuberger HR. Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension. 2013;61:225–31.

    Article  CAS  PubMed  Google Scholar 

  29. Ukena C, Bauer A, Mahfoud F, Schreieck J, Neuberger HR, Eick C. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol. 2012;101:63–7.

    Article  PubMed  Google Scholar 

  30. Moller JE, Helweg-Larsen J, Jacobsen E. Histopathological lesions in the sciatic nerve of the rat following perineural application of phenol and alcohol solutions. Dan Med Bull. 1969;16:116–9.

    CAS  PubMed  Google Scholar 

  31. Streitparth F, Walter A, Stolzenburg N, Heckmann L, Breinl J, Rinnenthal JL. MR-guided periarterial ethanol injection for renal sympathetic denervation: a feasibility study in pigs. Cardiovasc Intervent Radiol. 2013. doi:10.1007/s00270-013-0570-x.

    Google Scholar 

  32. Wali FA, Suer AH, Hayter A, Tugwell AC. The effect of ethanol on spontaneous contractions and on the contraction produced by periarterial nerve stimulation and by acetylcholine in the rat isolated ileum. Gen Pharmacol. 1987;18:631–5.

    Article  CAS  PubMed  Google Scholar 

  33. Kocabas H, Salli A, Demir AH, Ozerbil OM. Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. Eur J Phys Rehab Med. 2010;46:5–10.

    CAS  Google Scholar 

  34. Wilkes D, Ganceres N, Doulatram G, Solanki D. Alcohol neurolysis of the sciatic and femoral nerves to improve pressure ulcer healing. Pain Pract. 2009;9:145–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We wish to acknowledge the expert technical contributions of Jeff A. Burke, Phil C. Burke, Andy E. Denison, and Chris S. Hayden from REV-1 Engineering.

Disclosures, Conflict of Interest

TAF and VEG are principles, employees and co-founders of Ablative Solutions and have equity positions in the company. FV has is a paid consultant working with Ablative Solutions, Inc.

Author information

Authors and Affiliations

  1. Heart Institute at Borgess Medical Center, Kalamazoo, MI, USA

    Tim A. Fischell MD, FACC

  2. Ablative Solutions, Inc., Kalamazoo/Menlo Park, MI/CA, USA

    Tim A. Fischell MD, FACC & Vartan E. Ghazarossian PhD

  3. Preclinical Consultants, 53 Carmelita Street, San Francisco, CA, USA

    Félix Vega VMD

Authors
  1. Tim A. Fischell MD, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Félix Vega VMD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vartan E. Ghazarossian PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tim A. Fischell MD, FACC .

Editor information

Editors and Affiliations

  1. St. Luke's Medical Center, Phoenix, Arizona, USA

    Richard R. Heuser

  2. Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

    Markus Schlaich

  3. CardioVascular Center Frankfurt Sankt Katharinen, Frankfurt, Germany

    Horst Sievert

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Fischell, T.A., Vega, F., Ghazarossian, V.E. (2015). Perivascular Renal Denervation (PVRDTM): Chemical Renal Denervation with Micro-Doses of Ethanol Using the PeregrineTM Renal Denervation Device. In: Heuser, R., Schlaich, M., Sievert, H. (eds) Renal Denervation. Springer, London. https://doi.org/10.1007/978-1-4471-5223-1_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-5223-1_13

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-5222-4

  • Online ISBN: 978-1-4471-5223-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation